‘Sorafenib
Tosylate’ drug, which is sold as ‘Nexavar’, has hit the
headlines once again. Brushing off Bayer Corporation's claims, the
Bombay High Court ruled out the
German based drug maker's challenge of the Controller of Patents
decision to grant compulsory license to Natco Pharma Ltd, a Hyderabad
based pharmaceutical company. The court rejected Bayer’s plea and thus
declined to intervene with the Controller's original decision. A
division bench of Justice M S Sanklecha and Chief Justice Mohit Shah
observed that the rights of a patent holder of a drug or medicine should
not strip a patient from getting the required medication, and hence the
IPAB’s decision was upheld.
Let
me recap you briefly. The contenders in the arena are Bayer and Natco.
Sorafenib Tosylate, a drug used in the treatment of kidney and liver
cancer, was developed by Bayer and Onyx. It was traded under the name
‘Nexavar’. Bayer is a drug invention giant company, based in Germany. In
April 2011, an Indian company Natco Pharma Ltd, a generic medicine
maker, registered an application with the Bayer, asking for a voluntary
license to manufacture and distribute 'Nexavar' in India. The request
was refused and hence Natco went to the doors of the Controller of
Patents to apply for a compulsory license. According to the new WTO
rules, the then Controller of Patents, Mr. P.H. Kurian, on March 9th,
2012 granted Natco permission to manufacture generic version of Nexavar
in India. This judgment was a landmark in the history India’s Patent
Law, as it became the first ever case of compulsory licensing in India.
Surely this news broke all grounds, and Bayer was shown a cold cheek.
The
Controller General (CG) ascertained three reasons to justify its
decision. Firstly as Bayer provided Nexavar only to 2% of the total
cancer patient population in India, public requirements were far from
being met. Secondly, the pricing of the drug at Rs.2.8 Lakhs was
exorbitant and this was suffice to say that it was not a “reasonably
affordable” price. And lastly, it stated that Bayer has not shown proof
of the patented invention being “worked” in India.
The
order is completely justified. While it’s a well-known fact the
treatment process of cancer is extremely expensive, Bayer Corporation's
tactics of pricing the drug at a whooping Rs.2.84 lakhs does no good to
those in need. Given the fact that Bayer has invented this breakthrough
drug, I would place it on record, that, Natco is the Robin Hood to all
those people counting hopes and days by making the drug available at
Rs.8800. I mean, what good is a drug if the one who needs it can't
afford it? India is a country where millions still go to sleep hungry,
as the food produced does not reach everyone. At least we can expect the
medicine to be available to almost every patient who needs it. With
Natco now free to manufacture and distribute the drug, there’s another
reason for Cancer patients and Natco to celebrate this Diwali!
For more information, contact Lex Protector
Thanks for sharing about Sorafenib Tosylate. Its very Costly. If government provide low cost. Lots of cancer patients will survive. Thanks. Patent Search in India | Patent Valuation
ReplyDeleteBuy online Generic Alimta anti cancer medication.
ReplyDeleteWhen my partner and i acquired onto your internet site although acquiring thought fundamentally relatively little submits. Pleasant strategy for approaching, I will be bookmarking concurrently get sorts conclusion goes up up wards. Online Medicines
ReplyDelete